The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $231.12, a high ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Inspire Medical Systems (INSP – Research Report), with a ...

Stifel Nicolaus analyst Jonathan Block maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company ...

Chairman and Chief Executive Officer of Inspire Medical Systems. “We are also excited to announce the first implants of the new Inspire V neurostimulation system, and a new organizational ...

Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire”, or the "Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the“Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive ...

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday. Despite the robust preliminary results, the company’s shares plunged nearly ...

KeyBanc Capital Markets adjusted its price target on Inspire Medical Systems (NYSE:INSP) shares, lowering it to $234 from $236, while maintaining an Overweight rating on the stock. The revision ...